This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dabholkar, M. D. Articles by Reed, E. Search for Related Content PubMed PubMed Citation Articles by Dabholkar, M. D. Articles by Reed, E.

Malignant and Nonmalignant Brain Tissues Differ in Their Messenger RNA Expression Patterns for ERCC1 and ERCC2

Medical Ovarian Cancer Section, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 20892 [M. D. D., J. A. V., J. J. Y., E. R.]; Department of Neurological Surgery, University of Washington Medical Center, Seattle, Washington 98195 [M. S. B., J. R. S.]; and Laboratory of Immunology, National Eye Institute, Bethesda, Maryland 20892 [C. E.]

Perturbation of the DNA repair process appears to be responsible for the occurrence of a number of human diseases, which are usually associated with a propensity to develop internal malignancies and/or disorders of the central nervous system. We have been interested in the possibility that a subtle abnormality in DNA repair competency might be associated with the transformation of nonmalignant cells to the malignant state. To study this question, we assayed malignant and nonmalignant brain tissues from 19 individuals for mRNA expression levels of the human DNA repair genes ERCC1, ERCC2, and XPAC and for differential splicing of the ERCC1 transcript. We separately compared expression levels of these genes in the following situations: concordance of expression within malignant tissues; concordance of expression within nonmalignant tissues; concordance between malignant and nonmalignant tissues within individuals of the cohort; and concordance of gene expression between two nonmalignant tissue sites within a single individual. Linear regression analyses of mRNA values obtained suggested orderly concordance of these three DNA repair genes in nonmalignant tissues within the patient cohort and an excellent concordance of these genes between two separate biopsy sites from the same individual. In contrast, malignant tissues showed disruption of concordance between the full-length ERCC1 transcript and ERCC2, which have excision and helicase functions, respectively. Furthermore, within the same individuals, malignant tissues were discordant with nonmalignant tissues for ERCC1 and ERCC2, although concordance for XPAC was preserved. These data suggest that one molecular characteristic of human malignancy may be the disruption of the normal relationship between the excision and the helicase functions of the nucleotide excision repair pathway.

¹ To whom requests for reprints should be addressed, at Clinical Pharmacology Branch, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, Room 12N226, Bethesda, MD 20892.

Received 6/27/94. Accepted 1/18/95.

This article has been cited by other articles:

				R. McKean-Cowdin, J. Barnholtz-Sloan, P. D. Inskip, A. M. Ruder, M. Butler, P. Rajaraman, P. Razavi, J. Patoka, J. K. Wiencke, M. L. Bondy, et al. Associations between Polymorphisms in DNA Repair Genes and Glioblastoma Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1118 - 1126. [Abstract] [Full Text] [PDF]

				E. Reed ERCC1 and Clinical Resistance to Platinum-Based Therapy Clin. Cancer Res., September 1, 2005; 11(17): 6100 - 6102. [Full Text] [PDF]

				J. Viguier, V. Boige, C. Miquel, M. Pocard, B. Giraudeau, J.-C. Sabourin, M. Ducreux, A. Sarasin, and F. Praz ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6212 - 6217. [Abstract] [Full Text] [PDF]

				D. Isla, C. Sarries, R. Rosell, G. Alonso, M. Domine, M. Taron, G. Lopez-Vivanco, C. Camps, M. Botia, L. Nunez, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer Ann. Onc., August 1, 2004; 15(8): 1194 - 1203. [Abstract] [Full Text] [PDF]

				U. Warnecke-Eberz, R. Metzger, F. Miyazono, S. E. Baldus, S. Neiss, J. Brabender, H. Schaefer, W. Doerfler, E. Bollschweiler, H. P. Dienes, et al. High Specificity of Quantitative Excision Repair Cross-Complementing 1 Messenger RNA Expression for Prediction of Minor Histopathological Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3794 - 3799. [Abstract] [Full Text] [PDF]

				E. Reed, J. J. Yu, A. Davies, J. Gannon, and S. L. Armentrout Clear Cell Tumors Have Higher mRNA Levels of ERCC1 and XPB Than Other Histological Types of Epithelial Ovarian Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5299 - 5305. [Abstract] [Full Text] [PDF]

				L. O. Dragsted, B. Daneshvar, U. Vogel, H. N. Autrup, H. Wallin, L. Risom, P. Moller, A. M. Molck, M. Hansen, H. E. Poulsen, et al. A Sucrose-rich Diet Induces Mutations in the Rat Colon Cancer Res., August 1, 2002; 62(15): 4339 - 4345. [Abstract] [Full Text] [PDF]

				M. Caggana, J. Kilgallen, J. M. Conroy, J. K. Wiencke, K. T. Kelsey, R. Miike, P. Chen, and M. R. Wrensch Associations Between ERCC2 Polymorphisms and Gliomas Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 355 - 360. [Abstract] [Full Text]

				R. Perfetti, W. Lee-Kwon, C. Montrose-Rafizadeh, and M. Bernier Overexpression and Activation of the Insulin Receptor Enhances Expression of ERCC-1 Messenger Ribonucleic Acid in Cultured Cells Endocrinology, May 1, 1997; 138(5): 1829 - 1835. [Abstract] [Full Text] [PDF]